Calcium Antagonists

Precipitation of ceftriaxone-calcium can occur when mixed with calcium-containing solutions in the same IV line. Must not be administered simultaneously but can be given sequentially.

Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia such as hyperparathyroidism and those who form calcium-containing kidney stones.

Concomitant use may have additive effects resulting in hypotension and/or marked bradycardia.

May cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Should be avoided in patients with impaired cardiac function.

Precipitation of ceftriaxone-calcium can occur when mixed with calcium-containing solutions in the same IV line. Must not be administered simultaneously.

Products containing calcium may substantially decrease ciprofloxacin absorption, resulting in serum and urine levels considerably lower than desired.

Particularly if administered rapidly by IV route, may produce serious arrhythmias in digitalized patients.

May cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Should be avoided in patients with impaired cardiac function.

Caution advised; may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Avoid in patients with impaired cardiac function.

Isoflurane may lead to marked hypotension in patients treated with calcium antagonists.

Concomitant administration of high doses may increase risk of hypercalcemia. Monitor calcium frequently and adjust paricalcitol dose as needed.

Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored.

Addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided; precipitation or haze may result from sodium bicarbonate/calcium admixtures.

Co-administration may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension; should be avoided in patients with impaired cardiac function.

May cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. Should be avoided in patients with impaired cardiac function.

Caution recommended due to possible atrioventricular conduction disturbances, left ventricular failure, and hypotension. Coadministration should be avoided in patients with impaired cardiac function.

Caution advised due to possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. Avoid in patients with impaired cardiac function.

Calcium supplements interfere with absorption of alendronate sodium. Patients should wait at least one-half hour after taking alendronate sodium before taking calcium supplements.

Calcium supplements interfere with absorption of alendronate. Patients should wait at least 30 minutes after taking the medication before taking calcium supplements.

Uncontrolled intake of additional calcium-containing preparations should be avoided.

Uncontrolled intake of additional calcium-containing preparations should be avoided during calcitriol therapy.

Concomitant administration of high doses of calcium-containing preparations may increase the risk of hypercalcemia. Monitor serum calcium concentrations more frequently.

Absorption of tetracyclines is impaired by antacids containing calcium.

Calcium-containing antacids impair absorption of tetracyclines.

Calcium supplements interfere with absorption of ibandronate. Patients should take ibandronate at least 60 minutes before calcium supplements.

CNS depression and peripheral transmission defects produced by magnesium may be antagonized by calcium.

CNS depression and peripheral transmission defects from magnesium may be antagonized by calcium administration.

Absorption of tetracyclines is impaired by antacids containing calcium; may reduce minocycline effectiveness.

Calcium in antacids may bind phosphate and prevent its absorption.

Calcium supplements interfere with the absorption of risedronate when co-administered.

Coadministration may impair SEYSARA absorption and decrease efficacy. Separate dosing required.

Sodium bicarbonate should be avoided in admixtures with calcium-containing solutions; precipitation or haze may result.

May bind phosphate and prevent its absorption.

Possible additive effects on atrioventricular conduction, ventricular function, and blood pressure, potentially leading to hypotension.

High levels of calcium may alter biodistribution of technetium Tc 99m oxidronate, reducing skeletal uptake and increasing extraosseous uptake, potentially degrading imaging quality.

High levels of calcium from concomitant medications may alter biodistribution of technetium Tc 99m pyrophosphate, reducing skeletal uptake and increasing extraosseous uptake, potentially degrading imaging quality.

Calcium may reduce absorption of CUVRIOR. If concomitant use unavoidable, separate administration by at least 1 hour before or 2 hours after.

Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia.

Vitamin D supplementation should not be given with large amounts of calcium in those with hypercalcemia or conditions that may lead to hypercalcemia.

Used concomitantly with enalapril maleate without evidence of clinically significant adverse interactions.

Enalapril has been used concomitantly without evidence of clinically significant adverse interactions.